NEI Podcast E243 - A Look Back at This Year in Psychopharmacology with Dr. Roger McIntyre
12 snips
Dec 4, 2024 Dr. Roger McIntyre, a leading mental health expert in psychopharmacology, joins Dr. Andy Cutler to reflect on significant advances in the field this year. They dive into groundbreaking treatments for schizophrenia, discussing innovative drugs and their potential in improving cognitive and negative symptoms. The conversation also covers the complexities of prescribing anticholinergic medications and advancements in TMS therapy for adolescent depression. Insights on suicidality, mood disorders, and the interplay between sleep and mental health leave listeners with a deeper understanding of these crucial topics.
AI Snips
Chapters
Transcript
Episode notes
Kobenfi's Novel Mechanism
- Kobenfi (xenomeline and trospium) is a muscarinic agonist, unlike previous antipsychotics that primarily block dopamine receptors.
- This new mechanism avoids side effects like weight gain, metabolic issues, and movement disorders commonly associated with D2 blockers.
Kobenfi and Anticholinergics
- Avoid combining Kobenfi with anticholinergics due to potential systemic toxicity.
- Gradually taper patients off anticholinergics before starting Kobenfi, especially those with intrinsic anticholinergic activity.
Kobenfi Titration
- Titrate Kobenfi slowly, starting with the lowest dose for at least a week, for better tolerability.
- This approach goes beyond the package insert's recommendation of at least two days.